Sudan Loganathan
Stock Analyst at Stephens
(4.22)
# 1,473
Out of 5,023 analysts
36
Total ratings
58.8%
Success rate
22%
Average return
Main Sectors:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADCT ADC Therapeutics | Rated: Buy | $8 → $5 | $1.13 | +342.48% | 3 | Jun 4, 2026 | |
| PVLA Palvella Therapeutics | Initiated Coverage: Buy | $220 | $132.47 | +66.08% | 1 | May 11, 2026 | |
| IMNM Immunome | Rated: Buy | $33 → $30 | $20.90 | +43.54% | 3 | Mar 4, 2026 | |
| KYMR Kymera Therapeutics | Reiterated: Buy | $110 → $100 | $107.39 | -6.88% | 3 | Mar 2, 2026 | |
| ARVN Arvinas | Reiterated: Buy | $15 → $18 | $7.41 | +142.91% | 4 | Feb 25, 2026 | |
| PYXS Pyxis Oncology | Reiterated: Buy | $13 → $8 | $2.14 | +273.83% | 2 | Nov 24, 2025 | |
| CADL Candel Therapeutics | Initiated Coverage: Buy | $15 | $10.18 | +47.35% | 1 | Oct 28, 2025 | |
| CCCC C4 Therapeutics | Upgraded: Buy | $4 → $6 | $2.95 | n/a | 2 | Sep 15, 2025 | |
| FTH Faeth Therapeutics | Reiterated: Buy | $5 → $35 | $28.35 | n/a | 2 | Jun 30, 2025 | |
| EXEL Exelixis | Upgraded: Buy | $29 → $60 | $58.39 | n/a | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $30 | $22.99 | n/a | 2 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $8 → $1 | $0.365 | n/a | 2 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 → $5 | $1.17 | n/a | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $15 | $10.20 | n/a | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $51 | $37.36 | n/a | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $25 | $3.38 | n/a | 1 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $25 | $15.13 | n/a | 1 | May 13, 2024 |
ADC Therapeutics
Jun 4, 2026
Rated: Buy
Price Target: $8 → $5
Current: $1.13
Upside: +342.48%
Palvella Therapeutics
May 11, 2026
Initiated Coverage: Buy
Price Target: $220
Current: $132.47
Upside: +66.08%
Immunome
Mar 4, 2026
Rated: Buy
Price Target: $33 → $30
Current: $20.90
Upside: +43.54%
Kymera Therapeutics
Mar 2, 2026
Reiterated: Buy
Price Target: $110 → $100
Current: $107.39
Upside: -6.88%
Arvinas
Feb 25, 2026
Reiterated: Buy
Price Target: $15 → $18
Current: $7.41
Upside: +142.91%
Pyxis Oncology
Nov 24, 2025
Reiterated: Buy
Price Target: $13 → $8
Current: $2.14
Upside: +273.83%
Candel Therapeutics
Oct 28, 2025
Initiated Coverage: Buy
Price Target: $15
Current: $10.18
Upside: +47.35%
C4 Therapeutics
Sep 15, 2025
Upgraded: Buy
Price Target: $4 → $6
Current: $2.95
Upside: n/a
Faeth Therapeutics
Jun 30, 2025
Reiterated: Buy
Price Target: $5 → $35
Current: $28.35
Upside: n/a
Exelixis
Jun 24, 2025
Upgraded: Buy
Price Target: $29 → $60
Current: $58.39
Upside: n/a
Apr 9, 2025
Reiterated: Buy
Price Target: $20 → $30
Current: $22.99
Upside: n/a
Mar 24, 2025
Downgraded: Hold
Price Target: $8 → $1
Current: $0.365
Upside: n/a
Nov 19, 2024
Reiterated: Buy
Price Target: $25 → $5
Current: $1.17
Upside: n/a
Nov 18, 2024
Initiated Coverage: Buy
Price Target: $15
Current: $10.20
Upside: n/a
Nov 18, 2024
Initiated Coverage: Buy
Price Target: $51
Current: $37.36
Upside: n/a
Nov 7, 2024
Initiated Coverage: Hold
Price Target: $25
Current: $3.38
Upside: n/a
May 13, 2024
Rated: Buy
Price Target: $25
Current: $15.13
Upside: n/a